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Abstract
Background: The incidence, clinical outcomes and antithrombotic treatment spectrum of atrial fibrillation (AF) in
patients hospitalized with acute myocardial infarction (AMI) have not been well studied in Chinese population.
Methods: Twenty-six thousand five hundred ninety-two consecutive patients diagnosed with AMI were enrolled
in CAMI registry from January 2013 to September 2014. After excluding 343 patients with uncertain AF status and
1,591 patients transferred out during hospitalization, 24,658 patients were finally included in this study and involved
in analysis.
Results: In the CAMI registry, 740 (3.0%) patients were recorded with AF prevalence during hospitalization. Higher-
risk baseline clinical profile was observed in patients with AF. These patients were less likely to receive reperfusion/
revascularization than those without AF. The in-hospital mortality (including death and treatment withdrawal) was
significantly higher in patients with AF than that of without AF (25.2% vs. 7.2%, respectively; p < 0.01). The case of
composite of adverse events was similar, which included death, treatment withdrawal, re-infarction, heart failure or
stroke (42.1% vs. 16.0%, p <0.01). In multivariate logistic regression analysis, AF was an independent predictor for
in-hospital mortality (odds ratio, 1.88; 95% confidence interval: 1.27–2.78) and the composite of adverse events
(odds ratio, 2.11; 95% CI: 1.63–2.72). Only 5.1% of patients with AF were treated with warfarin, and 1.7% were
treated with both warfarin and dual antiplatelet therapy.
Conclusions: The analysis was based on the CAMI registry in China. The patients hospitalized for AMI who
developed AF were at significantly higher risk for in-hospital mortality and other adverse events. However,
the anticoagulants including warfarin have been largely underused post hospital discharge.
Trial registration: Clinical Trial Registration: Identifier: NCT01874691.
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Background
Atrial fibrillation (AF) is a common complication of
acute myocardial infarction (AMI). The reported inci-
dence of AF was widely ranged from 2.3 to 21.0%, with
an inconsistent relation to high mortality [1–12].
Although guidelines and consensus recommend a com-
bination of warfarin and dual antiplatelet therapy (DAPT)
and the duration was determined by hemorrhagic risk [13,
14], it was still complex to select an optimal antithrom-
botic regimen for patients with AF and AMI. Until now,
this triple therapy has been largely underused in real-
world clinical practice [15–17].
In China, AMI has become a major cause of emer-
gency medical care, hospitalization and death over the
past a few decades [18, 19]. The incidence, impact,
and antithrombotic therapy of AF in AMI have not
been correspondingly defined and demonstrated.
Present analysis was aimed to study this subject with
the data from China Acute Myocardial Infarction
(CAMI) registry [20]. The data of patients with AMI
were applied during January 2013 to September 2014.
The baseline characteristics, treatment strategy, clin-




The design of the CAMI registry has been demonstrated
in previous studies [20]. Briefly, this registry involved
three levels of hospitals (representing typical Chinese
governmental and administrative models) from all prov-
inces and municipalities throughout mainland China
(except for Hong Kong and Macau). Patients diagnosed
with AMI were eligible for inclusion in CAMI registry,
and were enrolled consecutively. Clinical data, treat-
ments and outcomes were collected by local investiga-
tors and captured electronically with a fixed table,
including a standardized set of variables and definitions,
under a rigorous data quality control. A total of 108
hospitals have participated in the registry after its launch
in January 2013 up to September 2014. This project was
approved by the institutional review board central com-
mittee at Fuwai Hospital, National Center for Cardiovas-
cular Diseases of China of China.
Inclusion and exclusion rules: the patients diagnosed
with AMI in involved hospitals during January 2013 up
to September 2014 were included. The patients were
excluded if AF status was missing or they were trans-
ferred out during hospitalization. For the main analysis
of in-hospital outcomes, the patients with truncated hos-
pital stay because of outside transfer were also excluded.
The presence of AF was documented by a standard 12-
lead electrocardiogram or electrocardiogram monitoring
during hospitalization.
In-hospital outcomes
The primary outcome of this study was in-hospital mor-
tality, which included death and treatment withdrawal
(withdrawal from all medical therapy or premature hos-
pital discharge). In China, many patients withdraw from
treatment at terminal status, which could be attributed to
the culture or financial affordability. Therefore, single in-
hospital mortality without accounting for these patients
could lead to an underestimate of actual in-hospital mor-
tality rates. Other recorded in-hospital clinical events
included: re-infarction, stroke, heart failure, a composite
of adverse events (the combination of death, treatment
withdrawal, re-infarction, heart failure or stroke), major
bleeding (including an absolute hemoglobin decrease of
3 g/dL, intracranial hemorrhage, any red blood cell trans-
fusion or a bleeding event requiring surgical repairing),
and any reported bleeding. Detailed definitions of clinical
events were previously demonstrated [20].
Statistical analyses
The patient baseline characteristics, medical history,
treatments, and complications were evaluated. Continu-
ous variables are presented as median (interquartile
range) and compared with Kruskal Wallis H test.
Categorical variables were presented as counts and
percentages, and were compared with chi-square or
Fisher’s exact tests.
Logistic regression analysis was applied to evaluate
the association between AF and in-hospital mortality or
the composite of adverse events. The variables included
in the multivariable model were either statistically sig-
nificant on univariate analysis (p <0.05) or clinically
critical, which were chosen by a stepwise method to
minimize colinearity. Included covariates were: sex, age
(>75 years), diabetes, hypertension, previous stroke,
previous myocardial infarction, prior percutaneous cor-
onary intervention (PCI)/coronary artery bypass graft
(CABG), ST-segment elevation myocardial infarction
(STEMI), serum creatinine, Global Registry of Acute
Coronary Events (GRACE) score >140, CHA2DS2-
VASc score >2, and reperfusion therapy. Crude and
adjusted odds ratios (ORs) and corresponding 95% con-
fidence intervals (CIs) were reported.
All comparisons were two-sided, with statistical sig-
nificance defined as p less than 0.05. Statistical analysis
was completed with SAS software, version 9.4.
Results
Twenty-six thousand five hundred ninety-two patients di-
agnosed with AMI were consecutively enrolled in CAMI
registry from January 2013 to September 2014. After ex-
cluding 343 patients with uncertain AF status and 1,591
patients who were transferred out during hospitalization,
24,658 patients were finally included in this analysis.
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Among them, 740 (3.0%) patients were recorded with AF
prevalence during hospitalization (Fig. 1).
Baseline characteristics of patients were shown (Table 1).
Compared with patients without AF, the age of patients
with AF were higher (mean age: 73 vs. 63 years, p <0.01),
more likely to be women (35.1% vs. 25.5%, p <0.01) and
with more comorbidities such as hypertension (59.3% vs.
51.2%, p <0.01), heart failure (7.7% vs. 2.4%, p < 0.01) and
stroke (17.8% vs. 9.2%, p < 0.01).Patients with AF were less
frequently presented with STEMI than those without AF
(65.7% vs. 76.0%, p <0.01), and had worse left ventricular
function. The proportions of CHA2DS2-VASc ≥2 (66.1%
vs.45.5%, p <0.01) and HAS-BLED ≥3 scores (21.4%
vs.10.8%, p <0.01) were significantly higher in patients
with AF, as well as the GRACE (161 vs.129,p <0.01) and
Thrombolysis in Myocardial Infarction (TIMI) scores
(6 vs.4,p <0.01). Patients with AF received reperfusion/
revascularization during hospitalization at a lower rate
than those without AF (35.9% vs. 48.3%, respectively,
p < 0.01), as the case for PCI(29.7% vs. 40.5%, respect-
ively, p <0.01).
The antithrombotic treatment regimens in AMI patients
with and without AF were summarized (Table 2). During
hospitalization, 78.0% of patients with AF received DAPT,
less than the rate of 86.3% in patients without AF (p <0.01).
However, the rates of anticoagulants treatment including
unfractionated heparin (UFH), low molecular weight hep-
arin (LMWH) and fondaparinux both groups were similar.
A majority of patients received DAPT (86.1%) and LMWH
(84.2%). Only 3.5% of patients with AF received warfarin,
which was nonetheless higher than the rate of 1.4% in pa-
tients without AF (p <0.01).
At hospital discharge, 76.2% of patients with AF re-
ceived DAPT, which was lower than the rate of 86.1% in
patients without AF (p <0.01). However, only 5.1% of
patients with AF were discharged on warfarin, and the
proportion of warfarin in combination with DAPT was as
low as 1.7%. In addition, no new direct oral anticoagulants
(dabigatran, rivaroxaban, and apixaban) were applied in
any patient.
The in-hospital outcomes were summarized (Table 3).
Rate of in-hospital mortality (death or treatment with-
drawal) was significantly higher in patients with AF
(25.2%) than that of without AF (7.2%) (p <0.01). The
rate of composite of adverse events (death, treatment
withdrawal, re-infarction, heart failure or stroke) was
also significantly higher in AF group (42.1% vs. 16.0%, p
<0.01), which was also the case for individual compo-
nent of the composite. In multivariate logistic regression
analysis, AF was an independent predictor for both in-
hospital mortality (odds ratio: 1.88, 95%CI: 1.27–2.78)
and the composite of adverse events (2.11, 95% CI:
1.63–2.72, respectively) (Figs. 2 and 3). The rate of major
bleeding was 1.7% in patients with AF, numerically
higher than the rate of 0.9% for patients without AF
(p =0.65).
Discussion
CAMI registry was the largest nationwide observational
study to date for hospitalized patients with AMI through-
out China. The major findings of present analysis were: 1)
the overall incidence of AF was 3.0% in Chinese patients
with AMI during hospitalization; 2) the risk of baseline
profile was higher in patients with AF than patients with-
out AF; 3) patients who developed AF were at a 1.88-fold
higher risk of in-hospital mortality than patients without
AF; and 4) although the majority of AMI patients compli-
cated with AF received anticoagulation and antiplatelet
Fig. 1 Population flow chart. AMI = acute myocardial infarction
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therapy during hospitalization, only 5.1% of them were
discharged on warfarin, and 1.7% were discharged on both
warfarin and DAPT.
In this nationally representative study, it firstly defined
an AF incidence of 3.0% in contemporarily treated AMI
patients in China. It was much lower compared to the
reported data in other countries, ranging from 2.3 to
21% [1–12]. It may be resulted from some possible










Age(years) 63 (53–72) 73 (65–
79)
63 (53–72) <0.01




28.2 32.0 28.0 0.02
PreviousMI 7.7 7.9 7.6 0.81
PreviousPCI/CABG 5.2 4.5 5.2 0.37
Previous heart failure 2.6 7.7 2.4 <0.01
Previous stroke 9.5 17.8 9.2 <0.01
Previous peripheral
arterial disease
0.6 1.1 0.6 0.15
Chronic renal failure 1.4 1.7 1.4 0.60
Cardiovascular risk factors
Hypertension 51.5 59.3 51.2 <0.01
Hyperlipidemia 8.0 6.3 8.1 0.10
Diabetes mellitus 20.0 18.8 20.0 0.44
Family history of
premature CAD
4.0 3.0 4.0 0.12
Current smoker 54.7 44.7 55.0 <0.01
Clinical characteristics
STEMI 75.7 65.7 76.0 <0.01
LVEF(%) 55(47–60) 50(41–59) 55(47–60) <0.01
Killip classification III-IV 9.2 24.2 8.7 <0.01
CHA2DS2-VASc≥ 2 46.1 66.1 45.5 <0.01
HAS-BLED ≥ 3 11.1 21.4 10.8 <0.01








STEMI 4 (2–6) 6 (4–8.5) 4 (2–6) <0.01
NSTEMI 2(2–3) 2(2–3) 2(1–3) <0.01
Treatments
Reperfusion Therapy 48.0 35.9 48.3 <0.01
PCI 40.2 29.7 40.5 <0.01
Fibrinolysis 7.8 6.2 7.8 <0.01
ACE/ARB 59.7 54.8 59.9 0.02
β-blockers 69.9 59.9 70.2 <0.01
Anti-arrhythmia drugs 9.8 45.4 8,7 <0.001
Data are presented as median (IQR) or %
AF atrial fibrillation, MI myocardial infarction, PCI percutaneous coronary
intervention, CABG coronary artery bypass graft, CAD coronary artery disease,
LVEF left ventricular ejection fraction, GRACE global registry of acute coronary
events, TIMI thrombolysis in myocardial infarction, STEMI ST-segment elevation
myocardial infarction, NSTEMI non-ST-elevation myocardial infarction, ACEI
angiotensin-converting enzyme, ARB angiotensin receptor blocker










DAPT 86.1 78.0 86.3 <0.01
UFH 5.9 5.2 5.9 0.43
LMWH 84.2 84.9 84.1 0.59
Fondaparinux 3.8 2.9 3.9 0.16
Warfarin 1.4 3.5 1.4 <0.01
At hospital discharge
DATP 85.9 76.2 86.1 <0.01
Warfarin 1.9 5.1 1.4 <0.01
Warfarin alone 0.3 1.0 0.3 0.02
Warfarin + single
antiplatelet drug
0.9 2.4 0.7 <0.01
Warfarin + DAPT 0.7 1.7 0.5 <0.01
AF atrial fibrillation, DAPT dual antiplatelet therapy, UFH unfractionated
heparin, LMWH low molecular weight heparin
aNot including anticoagulants administered in catheterization laboratory








Death 4.4 14.0 4.1 <0.01
Treatment
withdrawal
3.3 11.2 3.1 <0.01
Death + Treatment
withdrawal
7.7 25.2 7.2 <0.01
Re-infarction 0.6 1.4 0.6 0.02
Stroke 0.8 1.9 0.7 <0.01
Ischemic 0.6 1.4 0.5
Hemorrhagic 0.08 0.13 0.07
Unknown 0.11 0.4 0.09
Heart failure 16.7 42.1 16.0 <0.01
Composite of
adverse eventsa
19.2 47.5 18.4 <0.01
Major bleedingb 0.9 1.7 0.9 0.65
Any bleeding 1.8 2.7 1.8 0.09
aComposite of adverse events: death, treatment withdrawal, re-infarction, heart
failure or stroke
bMajor bleeding was defined as an absolute hemoglobin decrease of 3 g/dL,
intracranial hemorrhage, any red blood cell transfusion or a bleeding event
requiring surgical repair
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explanations. First, age was the most commonly reported
risk factor for AMI complicated with AF [21, 22], and
the low rate of AF in CAMI patients may be associated
with an overall lower mean age of 63 years in samples.
Second, 48.0% of overall patients in CAMI received re-
perfusion therapy (42.2% PCI). In previous studies,
widespread use of reperfusion therapy, especially PCI,
was associated with a notable decline of AF incidence
[11, 23]. Third, the majority of patients in CAMI were
treated with angiotensin-converting enzymes/angioten-
sin receptor inhibitors or β-blockers, and trials evaluat-
ing the effects of these drugs in patients with AMI have
reported lower incidence rates of AF, although mainly
making effects on late developing AF [24, 25]. Fourth,
ethnic differences may also account for the wide inci-
dence range of AMI complicated AF among different
countries. A recently published study reported a low
AF incidence of 2.7% in Arabian Gulf patients with
acute coronary syndrome (ACS) [4].
Consistent with previous studies [1–12], in CAMI regis-
try, higher-risk baseline clinical characteristics could be
observed in AMI patients complicated with AF during
hospitalization, including older age, a greater cardiovascu-
lar risk factor burden, more comorbidities, poorer left
ventricular function, and higher clinical risk scores. The
present study also documented that AMI patients with AF
were less likely to receive reperfusion/revascularization
than those without AF. For the patients with older age
and more comorbidities, more conservative management
approach would be selected by the physicians [26].
It indicated that AF increased the risk of morbidity
and mortality in patients with ACS, and that this associ-
ation would be mediated to a greater or lesser extent by
various comorbidities [1]. However, because of differ-
ences in study design and data availability, including
study population, AF classification, sample size, and
follow-up duration, the association between AF develop-
ment in ACS and increased in-hospital mortality
Fig. 2 Multivariable analysis of predictors of in-hospital mortality*. * In-hospital mortality included in-hospital death and treatment withdrawal.
LVEF = left ventricular ejection fraction; GRACE = Global Registry of Acute Coronary Events
Fig. 3 Multivariable analysis of predictors of the composite of adverse events*. *The composite of adverse events included in-hospital death, treatment
withdrawal, re-infarction, heart failure or stroke. GRACE = Global Registry of Acute Coronary Events; LVEF = left ventricular ejection fraction; MI =
myocardial infarction; STEMI = ST-segment elevation myocardial infarction; PCI = percutaneous coronary intervention; CABG = coronary artery
bypass graft
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remained to be controversial. Some variables were re-
ported to be independently associated with AF [2–9],
while others reported no association [10–12]. In present
analysis, the data was obtained from the CAMI registry,
which was a large-scale, national and contemporary
registry project for AMI patients in China [20]. The in-
hospital mortality was significantly higher in patients with
AF in unadjusted analysis. In addition, AF was also an inde-
pendent multivariate risk factor of mortality after adjusting
for possible confounders, although to an attenuated extent.
With the consistency of findings, the association was
further underscored in unadjusted and adjusted analyses.
The risk of bleeding may be increased by the anticoagu-
lants treatment combined with DAPT therapy for stroke
prevention in ACS patients with AF [27, 28]. However,
current guidelines and consensus recommend a com-
bination of warfarin and DAPT (triple therapy), with
adjustment of duration according to hemorrhagic risk
[13, 14]. Nonetheless, in previous studies, it docu-
mented that this triple therapy was largely underused,
with a frequency ranged from 5.7 to 15.6% [15–17]. In
the CAMI national registry, only 5.1% of AMI patients
with AF were discharged on warfarin, and the propor-
tion of warfarin in combination with DAPT was even
as low as 1.7%. The latter striking gap in China might
be secondary to many factors: the uncertainty about the
benefits of intense anticoagulation in these high risk
patients, inadequate provider knowledge, structural
inadequacies of healthcare delivery systems, and/or con-
cern about potential violence and litigation from patients
or their families due to complications associated with
treatment [29–31]. In addition, although new direct oral
anticoagulants (dabigatran, rivaroxaban, and apixaban)
have been approved for stroke prevention in non-valvular
AF patients [13], the CAMI registry indicated that these
new anticoagulants have not been applied yet in AMI
patients with AF in China.
CAMI registry was compared with REAL (REgistro
regionale AngiopLastiche dell’Emilia-Romagna) registry.
REAL registry was a multi-center, large scale, prospective
study [32–35]. It aimed to collect the clinical data of
coronary interventional cases from 4 million residents in
Emilia- Romagna. 13 hospitals participated in this registry.
The data could be retrieved in database. Many studies
were performed based on this database [36]. Similar to
REAL registry, CAMI has collected information of pa-
tients with acute myocardial infarction (AMI), including
the clinical data, treatment, efficacy and prognosis. It
aimed to improve the overall treatment efficacy of AMI in
China. However, CAMI has only focused the patients
from China. Different from REAL registry, CAMI has
involved 108 hospitals in Chinese mainland and the
hospitals differed in levels in CAMI registry. In addition,
the population base was larger in CAMI registry in China.
Finally, the involved cases were updated (since 2013). The
study based on CAMI would be promising in improving
the treatment efficacy of AMI in China.
Strengths and limitations
CAMI is the largest national registry of patients with
AMI. The population in the registry was representative
of different regions, economic strata and access to med-
ical resources in China. Therefore, the CAMI registry
can adequately reflect the current performance and sta-
tus of healthcare system in China. The data was valu-
able, specific and updated, which was based on a larger
population base. Nevertheless, our study has several
limitations. First, CAMI was subject to inherent limita-
tions and potential biases, including the collection of
nonrandomized data, missing or incomplete informa-
tion, and potential confounding by drug indications or
other unmeasured covariates which must be considered
in results interpretation. Second, our database did not
allow the identification of timing, type and duration of
AF (paroxysmal, persistent or permanent), as well as
the AF history, which may make effects on the progno-
sis prediction of the patients. Third, we do not include
the follow-up data after hospital discharge, including
both the mortality and other clinical events.
Conclusions
In China, AF development in patients with AMI was
associated with significantly higher in-hospital mortality,
and the anticoagulants including warfarin were largely
underused during hospitalization and after hospital
discharge. The conclusion on prediction and treatment
may be instructional towards both clinical practice and
further relevant studies.
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